Saturday, December 3, 2022

Dr. Paul Kearney Appointed Sera Prognostics Chief Data Officer

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Dr. Paul Kearney to the position of Chief Data Officer, effective October 1, 2021.

As the chief data/analytics officer, Dr. Paul Kearney will have responsibility to help direct, manage and analyze the large and growing data sets of Sera, both scientific and business, as Sera engages in studies designed to more fully characterize pregnancy and as commercial activities ramp during this phase of the company’s development.

“We are delighted to have Paul Kearney bring his extensive data science capabilities and experience to the Sera Prognostics team as we further our mission as The Pregnancy Company™,” said Gregory C. Critchfield, M.D., M.S., Chairman and CEO of Sera Prognostics. “Paul’s deep experience and fundamental understanding of data will help Sera build a solid bridge at the intersection of business, healthcare, bioinformatics, and innovation, where critical societal and clinical unmet needs can be addressed through partnerships, data exploration, and individualized maternal and prenatal healthcare. These approaches are most pertinent for Sera to effectively address healthcare disparities and enormous challenges that exist in pregnancy.”

Prior to joining Sera Prognostics, Dr. Kearney co-founded multiple successful biotech companies and data enterprises, resulting in the development and commercialization of breakthrough products in the disease areas of oncology, pregnancy, and food allergy, as well as technological products in bioinformatics and proteomics. He has extensive experience building and nurturing integrated teams, conducting clinical research, developing evidence for improved health outcomes, and fund raising. Dr. Kearney has published over 100 papers in diverse areas and has been awarded over 12 patents. Previously, he worked in positions at the Institute for Systems Biology, Integrated Diagnostics, Caprion (now CellCarta), Data Incites, Bioinformatics Solutions, and AllerGenis. Dr. Kearney received his Ph.D. in Bioinformatics/Computer Science from the University of Toronto and was a member of the Computer Science Faculty of the University of Waterloo.

“Sera Prognostics has an expansive and unique vision for utilizing novel biotechnology tools and innovative machine learning techniques to address the biggest clinical challenges associated with pregnancies,” said Dr. Kearney. “It is an enormous opportunity to partner with the world class team at Sera to address these challenges and improve health outcomes for mothers and babies.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
spot_img
spot_img

Our Sister Publication

Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy